InvestorsHub Logo
Followers 76
Posts 2459
Boards Moderated 0
Alias Born 09/07/2014

Re: sentiment_stocks post# 64712

Thursday, 06/16/2016 10:52:47 PM

Thursday, June 16, 2016 10:52:47 PM

Post# of 724126
Senti, since the DCVaxL trial is only seeking approval for new GBM nor recurring, is there any way that they can be approved by FDA for recurring GBM based on data from the EAP trial? Ever since the second trial was started for rapid progressors I've wondered if it could be used to prove the effectiveness of DCVaxL on rGBM. I know it doesn't have a control group, but the data we've seen is remarkable. I can't imagine FDA ignoring it.
Great thoughts. Thank you for sharing.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News